ATI RN · Pathophysiology · Pathophysiology Exam 1 Quizlet

Option A: Tamoxifen may increase the risk of venous thromboembolism, which is a critical point for patient education. This medication, while effective in treating breast cancer, has been associated with an elevated risk of blood clots, necessitating awareness and monitoring for signs of thromboembolic events during treatment.

Option B: Tamoxifen does not decrease the risk of osteoporosis; rather, it can have a neutral or potentially negative effect on bone density in postmenopausal women. Therefore, this statement misrepresents the medication's impact on bone health.

Option C: While tamoxifen can cause hot flashes and other menopausal symptoms, this option does not address the more serious risk of venous thromboembolism, which is a priority in patient education regarding this medication.

Option D: Tamoxifen is not primarily associated with weight gain and fluid retention. While some patients may experience these side effects, they are not the most significant concerns compared to the risk of thromboembolism.

Takeaways: Understanding that tamoxifen may increase the risk of venous thromboembolism is essential for patient safety and effective management during treatment.

Option B: It decreases bone resorption and increases bone density. Raloxifene is a selective estrogen receptor modulator (SERM) that mimics estrogen's beneficial effects on bone density by reducing the activity of osteoclasts, which are responsible for bone resorption. This action helps to maintain or improve bone density in patients with osteoporosis.

Option A: It stimulates the formation of new bone. Raloxifene does not directly stimulate new bone formation; rather, it primarily works by decreasing bone resorption, which is a different mechanism of action.

Option C: It increases calcium absorption in the intestines. Raloxifene does not enhance calcium absorption; its primary action is related to the modulation of bone resorption rather than intestinal calcium handling.

Option D: It increases the excretion of calcium through the kidneys. Raloxifene does not promote increased calcium excretion; its role is to decrease bone resorption, thereby preserving calcium in the bone rather than altering renal calcium handling.

Takeaways: Understanding the primary therapeutic action of raloxifene, which decreases bone resorption and increases bone density, is crucial for managing osteoporosis effectively and requires patient education on medication adherence to optimize treatment outcomes.

Option B: Fluid exudate is the primary cause of swelling during acute inflammation, resulting from increased vascular permeability that allows plasma proteins and fluids to leak into the interstitial space, leading to edema. This process is a key component of the inflammatory response, facilitating the delivery of immune cells to the site of injury or infection.

Option A: Collagenase is an enzyme that breaks down collagen, playing a role in tissue remodeling rather than directly causing swelling during inflammation.

Option C: Lymphocytic margination refers to the process of lymphocytes adhering to the endothelium of blood vessels, which is part of the immune response but does not directly contribute to the swelling associated with acute inflammation.

Option D: Anaerobic glycolysis is a metabolic pathway that generates energy without oxygen, not a direct cause of swelling in inflammation, which is primarily due to fluid accumulation.

Takeaways: The cause of swelling during acute inflammation is primarily due to fluid exudate, which results from increased vascular permeability and is essential for the inflammatory response and healing in affected tissues.

Option A: Lung cancer is the leading cause of cancer-related deaths in both men and women, accounting for a significant percentage of fatalities due to its aggressive nature and late presentation. Early detection remains challenging, contributing to its high mortality rate.

Option B: Breast cancer, while a common cancer among women, does not surpass lung cancer in terms of mortality rates across both genders. It is treatable when detected early, which reduces its overall death toll.

Option C: Colorectal cancer ranks as a significant cause of cancer deaths but is not as prevalent as lung cancer. Advances in screening have improved outcomes, further decreasing its mortality rate.

Option D: Prostate cancer primarily affects men and has a high survival rate, especially when diagnosed early. It does not account for as many deaths as lung cancer, making it less common as a cause of cancer-related mortality.

Takeaways: Lung cancer remains the most common cause of cancer-related deaths in both men and women, highlighting the importance of early detection and smoking cessation in reducing mortality rates.

Option A: Increased risk of liver dysfunction is a serious adverse effect that requires monitoring during testosterone therapy. Testosterone can lead to hepatic complications, including liver dysfunction and hepatic adenomas, particularly with high doses or prolonged use. Regular liver function tests are essential to detect any abnormalities early in patients receiving this therapy.

Option B: Increased risk of prostate cancer is a concern with testosterone therapy; however, current evidence does not definitively establish a causal relationship. While testosterone can stimulate prostate tissue, it does not directly cause prostate cancer, making it less critical to monitor than liver function.

Option C: Increased risk of bone fractures is not a primary concern with testosterone therapy. In fact, testosterone can improve bone density and reduce fracture risk in hypogonadal men, making this option less relevant for monitoring.

Option D: Increased risk of breast cancer is not typically associated with testosterone therapy in men. While there are rare cases of male breast cancer, the risk is not significantly elevated with testosterone treatment, thus making this option less pertinent for monitoring.

Takeaways: Monitoring for liver dysfunction during testosterone therapy is essential due to the potential for serious hepatic complications, emphasizing the need for regular liver function tests in patients undergoing this treatment.